The NOMA index is included in the complex of examinations of patients with obesity, diabetes mellitus, metabolic syndrome, polycystic ovary syndrome, chronic hepatitis C, and non-alcoholic liver steatosis to assess and monitor insulin resistance, the risk of developing diabetes mellitus and cardiovascular diseases.